
HCAT Stock Forecast & Price Target
HCAT Analyst Ratings
Bulls say
Health Catalyst Inc has demonstrated significant financial growth over the past seven years, highlighted by increasing EBITDA and a growing client base, despite a reduction in headcount, indicating operational efficiency. Many hospital executives have reported that their purchasing of Health Catalyst's modules is on the rise, along with positive volume trends that are ahead of budget expectations, suggesting strong demand for the company’s offerings. Moreover, as the acute care market stabilizes from previous economic pressures and improvements in volumes are observed, there is an anticipated rise in demand for Health Catalyst’s data and analytics solutions.
Bears say
Health Catalyst Inc. is facing a negative outlook primarily due to slowing total revenue growth and a highly penetrated total addressable market (TAM), raising concerns about future revenue and EBITDA growth. The company's recent performance highlighted a modest revenue and EBITDA beat for Q3; however, the 2026 revenue guidance indicates a forecast of 2-3% year-over-year declines alongside challenges such as client migration to a lower-cost platform and pressures on margins as top-line growth stagnates. Additionally, the impending departure of CEO Dan Burton and a decline in net dollar-based retention further exacerbate uncertainties regarding the company's future commercial viability and performance.
This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.
HCAT Analyst Forecast & Price Prediction
Start investing in HCAT
Order type
Buy in
Order amount
Est. shares
0 shares